What is the primary purpose of the new credit facility?

The new $5.0 billion revolving credit facility provides Thermo Fisher Scientific with enhanced financial flexibility for working capital needs, capital expenditures, acquisitions, stock repurchases, and refinancing of existing debt. It replaces a smaller, expiring credit facility.

How does this new credit facility benefit Thermo Fisher?

The larger credit facility ($5.0 billion vs $3.0 billion) and the option to extend it provides the company with greater financial resources and stability to pursue strategic opportunities and manage its operations effectively. The ability to increase the facility by an additional $1.0 billion further bolsters this flexibility.

What is the maturity date of the new credit facility?

The new credit facility matures on January 7, 2027. It also includes provisions for unlimited one-year extensions at the company's request, with lender consent, providing long-term access to these funds.

How will the company manage its debt obligations with these new facilities?

The company intends to use borrowings under the new credit facility strategically, ensuring it maintains sufficient borrowing capacity under its commercial paper programs to repay maturing commercial paper notes. The credit facility also requires adherence to a minimum consolidated net interest coverage ratio, indicating a commitment to maintaining healthy financial metrics.

TMO 8-K: Material Agreements & Financial Events

Summary

Thermo Fisher Scientific Inc. (TMO) has announced a significant upgrade to its financial flexibility through the establishment of a new $5.0 billion unsecured five-year revolving credit facility, effective January 7, 2022. This new facility substantially increases the company's borrowing capacity from its prior $3.0 billion facility and extends its maturity to 2027, with options for further one-year extensions. The increased credit line, along with an expansion option of up to $1.0 billion, provides Thermo Fisher with robust resources for various strategic initiatives including working capital, capital expenditures, acquisitions, stock repurchases, and debt refinancing. In conjunction with this, the company also intends to increase its U.S. and Euro commercial paper programs to a combined aggregate principal amount of up to $5 billion. This dual enhancement of its credit and commercial paper facilities signals a proactive approach by Thermo Fisher to ensure ample liquidity and financial agility to support its ongoing growth strategies and operational needs. The expanded credit lines are subject to customary covenants, including a minimum consolidated net interest coverage ratio, ensuring responsible financial management.

Key Highlights

1Established a new $5.0 billion unsecured five-year revolving credit facility, replacing the previous $3.0 billion facility.
2The new credit facility matures on January 7, 2027, with options for unlimited one-year extensions.
3Includes an expansion option allowing for up to an additional $1.0 billion in borrowings.
4Proceeds from the credit facility can be used for a wide range of corporate purposes, including working capital, capital expenditures, acquisitions, and stock repurchases.
5Plans to increase the aggregate principal amount outstanding for its U.S. and Euro commercial paper programs to up to $5 billion.
6The credit facility is subject to customary covenants, including a minimum consolidated net interest coverage ratio of 3.5 to 1.0.
7Borrowings under the credit facility are prepayable at the company's option without premium or penalty.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Jan 7, 2022)

Summary

Key Highlights

Frequently Asked Questions